Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose rituximab plus standard regimen for active neuropsychiatric lupus
ChiCTR2300070865Phase 4Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of rituximab in systemic lupus erythematosus (SLE) and neuropsychiatric systemic lupus erythematosus (NPSLE), sponsored by First Hospital of China Medical University. Primary endpoint: Improvement in BILAG nervous system score. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
rituximab
03
Conditions
systemic lupus erythematosus (SLE)neuropsychiatric systemic lupus erythematosus (NPSLE)
Beyond the preview
Go deeper on ChiCTR2300070865.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070865.